dc.contributor.author | Bazira, Joel | |
dc.contributor.author | Asiimwe, Benon B. | |
dc.contributor.author | Joloba, Moses L. | |
dc.contributor.author | Bwanga, Fred | |
dc.contributor.author | Matee, Mecky I | |
dc.date.accessioned | 2012-01-18T12:11:36Z | |
dc.date.available | 2012-01-18T12:11:36Z | |
dc.date.issued | 2010 | |
dc.identifier.citation | Bazira, J., Asiimwe, B.B., Joloba, M.L., Bwanga, F., Mecky I Matee, M.I. (2010). Use of the GenoType® MTBDRplus assay to assess drug resistance of Mycobacterium tuberculosis isolates from patients in rural Uganda. BMC Clinical Pathology 2010, 10(5) | en_US |
dc.identifier.issn | 1472-6890 | |
dc.identifier.uri | http://hdl.handle.net/10570/330 | |
dc.description.abstract | Background: Drug resistance levels and patterns among Mycobacterium tuberculosis isolates from newly diagnosed and previously treated tuberculosis patients in Mbarara Uganda were investigated. Methods: We enrolled, consecutively; all newly diagnosed and previously treated smear-positive TB patients aged ≥ 18 years. Isolates were tested for drug resistance against rifampicin (RIF) and isoniazid (INH) using the Genotype® MDRTBplus assay and results were compared with those obtained by the indirect proportion method on Lowenstein-Jensen media. HIV testing was performed using two rapid HIV tests. Results: A total of 125 isolates from 167 TB suspects with a mean age 33.7 years and HIV prevalence of 67.9% (55/81) were analysed. A majority (92.8%) of the participants were newly presenting while only 7.2% were retreatment cases. Resistance mutations to either RIF or INH were detected in 6.4% of the total isolates. Multidrug resistance, INH and RIF resistance was 1.6%, 3.2% and 4.8%, respectively. The rpob gene mutations seen in the sample were D516V, S531L, H526Y H526 D and D516V, while one strain had a Δ1 mutation in the wild type probes. There were three strains with katG (codon 315) gene mutations while only one strain showed the inhA promoter region gene mutation. Conclusion: The TB resistance rate in Mbarara is relatively low. The GenoType® MTBDRplus assay can be used for rapid screening of MDR-TB in this setting | en_US |
dc.language.iso | en | en_US |
dc.publisher | BioMed Central | en_US |
dc.subject | Mycobacterium tuberculosis | en_US |
dc.subject | TB (Disease) | en_US |
dc.subject | Pulmonary tuberclosis | en_US |
dc.subject | Lungs-Diseases | en_US |
dc.subject | Lungs-Tuberclosis | en_US |
dc.subject | HIV/AIDS | en_US |
dc.subject | Multidrug Resistant-Tuberclosis (MDR-TB) | en_US |
dc.subject | Consumption (Disease) | en_US |
dc.title | The use of Genotype MTBDRplus assay to assess drug resistance of microbacterium tuberculosis isolates from patients in rural Uganda | en_US |
dc.type | Journal article, peer reviewed | en_US |
dc.type | Journal article, preprint | en_US |
dc.type | Learning Object | en_US |